[go: up one dir, main page]

MX2009010269A - Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. - Google Patents

Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.

Info

Publication number
MX2009010269A
MX2009010269A MX2009010269A MX2009010269A MX2009010269A MX 2009010269 A MX2009010269 A MX 2009010269A MX 2009010269 A MX2009010269 A MX 2009010269A MX 2009010269 A MX2009010269 A MX 2009010269A MX 2009010269 A MX2009010269 A MX 2009010269A
Authority
MX
Mexico
Prior art keywords
combinations
methods
human
treating cancer
administering human
Prior art date
Application number
MX2009010269A
Other languages
English (en)
Inventor
Stephen H Trulli
Zdenka Haskova
Zdenka Ludmila Jonak
Margaret N Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX2009010269A publication Critical patent/MX2009010269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere en general al uso de combinaciones de la IL-18 humana en el tratamiento de diversas formas de tumores sólidos y linfomas. En particular, la presente invención se refiere a: (1) combinaciones de la IL-18 humana con anticuerpos monoclonales contra antígenos que se expresan en la superficie de células cancerosas; y (2) combinaciones de IL-18 humana con agentes terapéuticos.
MX2009010269A 2007-03-23 2008-03-20 Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. MX2009010269A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26
PCT/US2008/057615 WO2008118733A2 (en) 2007-03-23 2008-03-20 Methods of treating cancer by administering human il-18 combinations

Publications (1)

Publication Number Publication Date
MX2009010269A true MX2009010269A (es) 2009-10-12

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009010269A MX2009010269A (es) 2007-03-23 2008-03-20 Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
MX2009010271A MX2009010271A (es) 2007-03-23 2008-03-20 Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009010271A MX2009010271A (es) 2007-03-23 2008-03-20 Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.

Country Status (21)

Country Link
US (4) US20090035258A1 (es)
EP (3) EP2129398A4 (es)
JP (2) JP2010522200A (es)
KR (2) KR20100015798A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231025A1 (es)
BR (2) BRPI0809079A2 (es)
CA (2) CA2681827A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970885A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31265B1 (es)
MX (2) MX2009010269A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118736A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206277A (zh) * 2000-02-10 2011-10-05 雅培制药有限公司 结合人白介素-18的抗体及制备和使用方法
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
LT3134124T (lt) 2014-04-25 2019-05-27 Pierre Fabre Médicament Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui
PT3134125T (pt) 2014-04-25 2020-01-13 Pf Medicament Conjugado-fármaco-anticorpo e sua utilização para o tratamento de cancro
CA2957387A1 (en) * 2014-08-07 2016-02-11 Hyogo College Of Medicine Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20240368247A1 (en) * 2020-12-02 2024-11-07 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (ja) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
PL208592B1 (pl) * 2000-06-15 2011-05-31 Smithkline Beecham Corp Sposób wytwarzania aktywnego ludzkiego polipeptydu IL-18 z ludzkiego polipeptydu prekursora IL-18
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
CN101914158A (zh) * 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
US20040001828A1 (en) * 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
ATE497778T1 (de) * 2002-09-16 2011-02-15 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
WO2004032962A1 (en) * 2002-10-08 2004-04-22 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
SI1558648T1 (sl) * 2002-10-17 2012-05-31 Genmab As Človeška monoklonalna protitelesa proti CD
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
WO2004091517A2 (en) * 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
RU2412199C2 (ru) * 2005-04-18 2011-02-20 Ново Нордиск А/С Варианты ил-21
KR20080030673A (ko) * 2005-07-21 2008-04-04 젠맵 에이/에스 Ｆｃ 수용체와 결합하는 항체 약품 성분에 대한 효력 검정
WO2008008981A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CA2662609A1 (en) * 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation of regulatory t cells by human il-18
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18

Also Published As

Publication number Publication date
AR065803A1 (es) 2009-07-01
KR20100015798A (ko) 2010-02-12
SG171674A1 (en) 2011-06-29
AU2008231114A1 (en) 2008-10-02
CL2008000818A1 (es) 2008-09-26
EP2129398A4 (en) 2010-04-21
CR11075A (es) 2010-03-22
IL200863A0 (en) 2010-05-17
AR065818A1 (es) 2009-07-01
DOP2009000208A (es) 2010-03-31
EP2136841A4 (en) 2010-07-07
KR20100014530A (ko) 2010-02-10
AU2008231025A1 (en) 2008-10-02
TW200904469A (en) 2009-02-01
NZ579179A (en) 2011-12-22
MX2009010271A (es) 2009-10-12
CR10996A (es) 2009-11-12
WO2008118733A3 (en) 2008-11-27
CA2681827A1 (en) 2008-10-02
US20100196310A1 (en) 2010-08-05
BRPI0809079A2 (pt) 2019-03-06
CL2008000842A1 (es) 2008-10-17
PE20090184A1 (es) 2009-03-22
BRPI0808943A2 (pt) 2014-08-26
WO2008118733A2 (en) 2008-10-02
MA31264B1 (fr) 2010-03-01
EP2129398A1 (en) 2009-12-09
JP2010522239A (ja) 2010-07-01
WO2008118736A1 (en) 2008-10-02
MA31265B1 (fr) 2010-03-01
DOP2009000220A (es) 2009-10-31
EP2338514A1 (en) 2011-06-29
IL200525A0 (en) 2010-04-29
JP2010522200A (ja) 2010-07-01
EA200970885A1 (ru) 2010-02-26
EA200970884A1 (ru) 2010-04-30
CN101678102A (zh) 2010-03-24
US20090035258A1 (en) 2009-02-05
TW200906436A (en) 2009-02-16
PE20090190A1 (es) 2009-03-22
EP2136841A2 (en) 2009-12-30
CA2681851A1 (en) 2008-10-02
US20080274078A1 (en) 2008-11-06
US20100111945A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
IL184617A0 (en) Dr5 antibodies and uses thereof
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
TW200612918A (en) Lonidamine analogs
PH12013500826A1 (en) Means and methods for treating dlbcl
WO2010059969A8 (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
UA105760C2 (uk) Антитіло проти bst2
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006116451A3 (en) Antibodies with immune effector activity and that internalize in endosialin-positive cells
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
WO2006116001A3 (en) Antibodies for the treatment of cancers

Legal Events

Date Code Title Description
FA Abandonment or withdrawal